In this section

Karadimitris Lab

Contact

Anastasios Karadimitris PhD, MRCP, FRCPath

Professor of Haematology and Consultant Haematologist
Director of Centre

+44 (0)20 3313 4017
a.karadimitris@imperial.ac.uk

Areas of research

Regulatory genomics of multiple myeloma

Primary and secondary genetic events underpin the transcriptional changes that drive myeloma oncogenic transcriptional programmes. These are executed by deregulated transcription factors and chromatin binding proteins. Our aim is to understand the role of known and novel transcription factors/chromatin modifiers in the biology of multiple myeloma and discover and validate therapeutic targets.

Our experimental tools include -omics assays (ChIP-seq, ATAC-seq, RNA-seq, Capture-C), chromatin proteomics, gene editing approaches including CRISPRi and relevant in vitro and in vivo models of multiple myeloma.

Immunotherapy of multiple myeloma

The Karadimitris group have been studying the biology and therapeutic potential of invariant NKT cells (iNKT) in acute graft-versus-host disease (aGVHD) and blood cancers. They showed that donor iNKT cells protect recipients of allogeneic stem cell transplant from aGVHD and iNKT cell equipped with chimaeric antigen receptor against CD19 (CAR19-iNKT) outperform CAR19-T cells in pre-clinical models of B cell lymphoma. Following this lead, the group is now developing CAR-iNKT cell-based immunotherapy against MM that includes development and validation of CAR against established and novel targets.

Our experimental tools include short- and long term in vitro assays (including longitudinal Incucyte live-cell imaging) and xenograft animal models of blood cancers and myeloma.

In parallel to pre-clinical studies, the group are pursuing clinical development of the CAR-iNKT cell platform for blood cancers.

Citation

BibTex format

@article{Chaidos:2013:10.1182/blood-2012-06-436220,
author = {Chaidos, A and Barnes, CP and Cowan, G and May, PC and Melo, V and Hatjiharissi, E and Papaioannou, M and Harrington, H and Doolittle, H and Terpos, E and Dimopoulos, M and Abdalla, S and Yarranton, H and Naresh, K and Foroni, L and Reid, A and Rahemtulla, A and Stumpf, M and Roberts, I and Karadimitris, A},
doi = {10.1182/blood-2012-06-436220},
journal = {BLOOD},
pages = {318--328},
title = {Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma},
url = {http://dx.doi.org/10.1182/blood-2012-06-436220},
volume = {121},
year = {2013}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AU  - Chaidos,A
AU  - Barnes,CP
AU  - Cowan,G
AU  - May,PC
AU  - Melo,V
AU  - Hatjiharissi,E
AU  - Papaioannou,M
AU  - Harrington,H
AU  - Doolittle,H
AU  - Terpos,E
AU  - Dimopoulos,M
AU  - Abdalla,S
AU  - Yarranton,H
AU  - Naresh,K
AU  - Foroni,L
AU  - Reid,A
AU  - Rahemtulla,A
AU  - Stumpf,M
AU  - Roberts,I
AU  - Karadimitris,A
DO  - 10.1182/blood-2012-06-436220
EP  - 328
PY  - 2013///
SN  - 0006-4971
SP  - 318
TI  - Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma
T2  - BLOOD
UR  - http://dx.doi.org/10.1182/blood-2012-06-436220
UR  - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000313726400012&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
VL  - 121
ER  -

Download